The U.S. Food and Drug Administration (FDA) announced the approval of Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation.
In the overall clinical trial population, patients who received Tagrisso had an 80 percent decrease in disease recurrence chance compared with patients who received a placebo, stated the FDA.
First Adjuvant Treatment for Non-Small Cell Lung Cancer Approved
U.S. FDA Issues Emergency Authorization for Second COVID-19 Vaccine
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the Moderna COVID-19 Vaccine for distribution in the USA for use in individuals 18 years of age and older.
The Moderna COVID-19 Vaccine (mRNA-1273) contains messenger RNA (mRNA), which is genetic material.
Announced on December 18, 2020, this is the second FDA authorization of an experimental vaccine to prevent COVID-19.